| Name | Title | Contact Details |
|---|
Pillar Biosciences aims to "Make precision medicine the first option for every patient" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today`s high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%. Current as of May 25, 2021.
Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.
BiomedAIliance is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HudsonAlpha Institute seeks to expand the science of human genomics and hasten its movement into the marketplace where discoveries can benefit society.